Breakthrough drug treatment for bronchopulmonary dysplasia

Bronchopulmonary dysplasia (BPD) is a common paediatric disease which causes damage to lung tissue and inhibits normal lung growth in pre-term babies. This often results in impaired neurodevelopment, increased susceptibility to developing respiratory infections and increased hospitalisations, creating a huge burden on both the baby and their family.

However, researchers at the Hudson Institute of Medical Research have recently developed two anti-inflammatory drugs that they believe could prevent the development of BPD. According to senior researcher Dr Ina Rudloff, the drugs have been used previously in other diseases, which will hopefully ensure that they have a safe and effective outcome once clinical trials are over.

Tushar Goyal

Read more here.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s